Latest From Synlogic Inc.
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.
The synthetic biotics company is discontinuing development of SNYB1020, its first clinical-stage product, which failed to lower blood ammonia in cirrhosis patients.
Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.
Palynziq has received European Commission approval to treat phenylketonuria a year after the US FDA gave it the green light. BioMarin now markets the only two approved treatments for the condition.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- Hepatic (Liver)
- Immune Disorders
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- Synlogic Inc.
- Senior Management
Aoife M Brennan, MD, Pres. & CEO
Gregg Beloff, Interim CFO
Scott Plevy, MD, CSO
Richard Riese, MD, PhD, CMO
Michael Slater Slater, Head, Reg. Affairs
- Contact Info
Phone: (617) 401-9975
301 Binney St.
Cambridge, MA 02142
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.